zardaverine has been researched along with Liver Neoplasms in 1 studies
zardaverine: structure given in first source
zardaverine : A pyridazinone derivative in which pyridazin-3(2H)-one is substituted at C-6 with a 4-(difluoromethoxy)-3-methoxyphenyl group. It is a phosphodiesterase inhibitor, selective for PDE3 and 4.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, L | 1 |
| Quan, H | 1 |
| Xie, C | 1 |
| Wang, L | 1 |
| Hu, Y | 1 |
| Lou, L | 1 |
1 other study available for zardaverine and Liver Neoplasms
| Article | Year |
|---|---|
Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line | 2014 |